Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release December 13, 2019, at 9:45 a.m. Nokian Tyres has received an announcement from Bridgestone Corporation on December 13, 2019, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement Bridgestone Corporation’s direct holding in Nokian Tyres shares fell below the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on December 12, 2019. The direct shareholding was 4,167,653 shares, representing 3.00% of Nokian Tyres’ 138,921,750 shares and voting rights.

Idogen files patent application for new tolerogenic cell therapy

Idogen AB (Spotlight Stock Market: IDOGEN) announced today that the company has filed a patent application for its new, innovative method for cell therapy. The method is based on a unique combination of tolerance-inducing substances that have shown good results in preclinical trials. The patent application covers Idogen’s entire technology platform for tolerogenic cell therapy and the application provides a right of priority and is a first step towards a global expansion to all major markets. Granting will provide market exclusivity until 2040.Idogen’s tolerogenic dendritic cells are

Hansa Biopharma has agreed with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S.

Lund, Sweden December 13, 2019 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced the outcome of a November 20th meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients. Upon agreement with the FDA, following submission of a final study protocol, the Company will conduct a randomized, controlled clinical study in a limited group of highly sensitized kidney patients using a surrogate endpoint. Results from this clinical

A new gas filling station opens in Mariestad, Sweden to further expand the Nordic network

The Nordic gas filling station network continues its rapid growth as energy company Gasum opens a new station in Mariestad, Sweden. This is Gasum’s seventh liquefied gas filling station for heavy-duty vehicles in Sweden, and the first Gasum filling station in Västra Götaland. This filling stations is a part of Gasum’s expanding network planning to have a network of 50 filling stations for heavy-duty vehicles by the early 2020s in the Nordics as the demand for cleaner fuel solutions continues to grow.The new gas filling station in Mariestad, Sweden will go into service on December 13. The

Enzymatica in agreement for enzyme formulations for the Chinese skin care market

Enzymatica’s subsidiary Zymetech has entered a non-exlusive agreement with Dr Bragi Company Ltd for the sales and delivery of three different enzyme formulations based on Enzymatica’s patented enzyme technology, which will be used in Dr Bragi Company’s skin care products. It is a five-year agreement covering China and parts of Asia. Dr Bragi Company has placed an initial order of about SEK 0.8 million for delivery at year-end  2019. Follow-up orders are expected in 2020. The agreement of formulations based on Enzymatica’s patented enzyme technology is the second agreement, after the agreement

Scott Rafkin appointed Volvo Group Chief Digital Officer

Scott Rafkin, currently President of Volvo Financial Services, has been appointed to the new position of Executive Vice President and Chief Digital Officer for the Volvo Group, effective January 1, 2020. In this role he will be a member of the Executive Board and report to the Volvo Group President and CEO Martin Lundstedt.Born in 1969, Scott Rafkin has served as President of Volvo Financial Services since 2014. He joined the Volvo Group in 2001 and has since held several managerial positions within Volvo Financial Services, including that of Chief Financial Officer.  As Chief Digital

Climeon completes Sea Trials with Virgin Voyages and Fincantieri

Climeon has successfully passed the SeaTrials for Virgin Voyages first ship, the Scarlet Lady.  At the end of 2017, Climeon passed the Factory Acceptance Test for the first order from Virgin Voyages and Fincantieri. Since then, the modules have been installed onboard Virgin Voyages first ship, the Scarlet Lady. Now another big milestone has been reached as the ship, including the Heat Power modules, has successfully completed the Sea Trials, where the ship is tested at sea for the first time. - This is a big milestone for Climeon, we have been working towards this goal for many years.

The TagMaster Nominating committee for 2020 is confirmed

Pressrelease, Stockholm, Sweden, December 13, 2019 The TagMaster Nominating committee for the AGM in April 2020 has been confirmed. Gert Sviberg, the company’s biggest shareholder, will be its chairman. Further members are Tomas Brunberg as the third biggest shareholder and Jean Francois Paumelle representing Eiffel Investment Group being the second biggest shareholder together with Marie-Louise Gefwert representing the smaller share holders and Rolf Norberg, chairman of the company. The Nominating committee has also decided to co-opt Didrik Hamilton being the fourth biggest shareholder.

CELLINK’s board has set financial targets for the company

CELLINK’s financial targets for the period 2019-2022 are as follows: CELLINK’s goal is to grow sales organically with a minimum of 35% per year and grow additionally through acquisitions. CELLINK’s Board targets a profitable growth, therefore CELLINK shall show a positive EBITDA margin during the period 2019-2022. CELLINK’s board considers that CELLINK should have a strong capital base in order to enable continued high growth, both organically and through acquisitions. The company’s net debt in relation to EBITDA should normally not exceed 3 times.  Goals in summary: · Organic

Bonava to donate SEK 250,000 to Doctors Without Borders

Bonava has chosen to donate this year’s Christmas gift of SEK 250,000 to Doctors Without Borders. Instead of giving out Christmas gifts to employees, Bonava has prioritised a donation to an organisation that helps people in need.– Instead of Christmas gifts to all our employees, we donated the money to people in need. Doctors Without Borders has great credibility and knowledge as regards tangible help for people in need. No-one can do everything, but everyone can do something, says Joachim Hallengren, President and CEO of Bonava. To decide who would receive the donation for 2019, Bonava

HKScan’s repurchases of own shares have been completed

HKScan Corporation, Stock Exchange Release, 13 December 2019, at 9:00 (EET)HKScan’s repurchases of own shares have been completed HKScan Corporation has completed the buy-back programme concerning the company’s own series A shares, the start of which was announced by the company on 25 September 2019. In trading organised by Nasdaq Helsinki Ltd, the company has between 1 October 2019 and 12 December 2019 acquired a total of 2 000 000 of its own series A shares with an average price of EUR 2.3614 per share. The total purchase price for the shares was EUR 4.7 million. On 13 December 2019,

Altor to divest Ålö to JOST

Altor Fund III (“Altor”), Fort Knox Förvaring AB and Management Investors have today signed an agreement to divest Ålö Holding AB (“Ålö”), a world leader within material handling solutions in the agricultural industry to JOST Werke AG (“JOST”). JOST is a world leading supplier of systems to the Truck and Trailer Industry.Ålö is a global market leader in top-quality front loaders and associated implements for agricultural tractors, with sales in more than 40 countries. Front loaders and implements are sold under the Quicke brand as well as in cooperation with tractor OEMs. The company has

New environmentally friendly barrier paper for food packaging

Paper based packaging that is used in bakeries, food outlets and quick service restaurants (QSR) often contains a treatment of a non-decomposable high-fluorinated chemical, known as PFAS.  Now BillerudKorsnäs is launching Repel Pure, a paper where the grease-resistant barrier is plant-based and totally biological.“Today we see an increasing demand for alternatives to PFAS treated products.  After working a long time to find a sustainable alternative to surface treatment with high-fluorinated substances, we are today very proud to present our paper Repel Pure,” says Helene Biström, Executive

Change in Kesko’s Group Management Board

Kesko Corporation is reorganising its Legal Affairs function. Lasse Luukkainen, Master of Laws, 41, has been appointed Kesko’s Group General Counsel as of 1 January 2020. He will also act as Company Secretary for Kesko's Board of Directors and its Committees and the Group Management Board. Luukkainen has worked at Kesko Corporation in various legal positions since 2010, most recently as Senior Corporate Counsel for Kesko’s grocery trade and Secretary to Group Management Board. Luukkainen will report to President and CEO Mikko Helander. Kesko’s current Group General Counsel and member of

Fastpartner raises SEK 714 million in equity

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, CANADA, NEW ZEELAND, JAPAN, SWITZERLAND, OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. ADDITIONAL RESTRICTIONS ARE APPLICABLE. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT.Fastpartner AB (publ) (“Fastpartner”) has issued 8,500,000 common shares of series D. The price in the offer was set to SEK 84 per D-share following a book building process.

New free Expeditions mode now available for critically acclaimed "Control"

Remedy Entertainment Plc | Press release 7:45 am (EET) 13 December 2019 2019 Game of the Year (IGN, Official PlayStation Magazine) and Winner of Best Art Direction from The Game Awards Releases Free December Update on All Platforms for the Supernatural Action-Adventure Game Watch the Game Awards Trailer Here: youtu.be/voko5U5lGFU Global videogame publisher 505 Games  and its partner, internationally renowned developer Remedy Entertainment , have released a free December update for the third-person action-adventure game Control (

IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL PURSUANT TO APPLICABLE RULES OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. The board of directors of IRLAB Therapeutics AB (publ) (the “Company” or “IRLAB”) has, based on the authorization granted by the annual general meeting on 25 April 2019, resolved to carry out a directed issue of new shares of series A of approximately SEK 70 million to

Final result of SBB’s rights issue

Read more at: http://www.sbbnordeninfo.se/ For additional information, please contact: Ilija Batljan, CEO and Founder of Samhällsbyggnadsbolaget i Norden AB, +46 70 518 39 67, ilija@sbbnorden.se The information was sent for publication, through the agency of the contact person set out above, on December 12, 2019, at 22:00 (CET). About Samhällsbyggnadsbolaget i Norden AB (publ) The company’s strategy is to own, manage and develop community service properties throughout the Nordic region and rental apartments in growth regions in Sweden. Through the company's commitment and

Significant effect of Diamyd[®] in Type 1 diabetes shown in a new comprehensive analysis of previous Phase III and Phase II trials

Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and US with the diabetes vaccine Diamyd® has identified genetically defined subgroups of type 1 diabetes patients that show a positive and statistically significant dose-dependent treatment response.In the analysis, patients who were positive for certain HLA genotypes and treated with the highest number of doses of Diamyd® (three and four subcutaneous injections) experienced a statistically significant treatment effect of approximately 60%

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Nordic Waterproofing Holding A/S’ shares

In accordance with article 19 of Market Abuse Regulation, Nordic Waterproofing Holding A/S, hereby notifies receipt of information of the following transactions in the company's shares made by persons discharging managerial responsibilities and persons closely associated with them.1 Details of the person discharging managerial responsibilities/person closely associated   a) Name: Thomas Zipfel 2. Reason for the notification a) Position/Status:  Member of the Management team of Nordic Waterproofing Holding A/S, Head of SealEco b) Initial notification/Amendment: Initial

The prospectus for Brighter’s rights issue is now available

The prospectus that has been produced on the basis of the rights issue initially announced on November 18, and changed earlier today, has now been approved and registered by the Swedish Financial Supervisory Authority. The prospectus will be available on the company's website. The prospectus states that trading in BTA begins on December 13, 2019, which is incorrect. Trading in BTA will begin on December 18, 2019. For further information, please contact: The Board of Directors: styrelsen@brighter.se Ann Zetterberg, CFOPhone: +46 708 37 21 23Email: ann.zetterberg@brighter.se

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

OPTOMED PLC          STOCK EXCHANGE RELEASE                      12 December 2019 at 8 p.m. Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Universal-Investment-Gesellschaft mit beschränkter Haftung (“Universal Investments”). According to the notification, the total holdings in Optomed shares and votes held by Universal Investments has increase to 7.49 per

Dining Packages and Specials for California Restaurant Month

SACRAMENTO, CA [December 12, 2019]—In celebration of California Restaurant Month in January, the California Association of Boutique and Breakfast Inns (CABBI.com ) has compiled a list of B&Bs and boutique hotels offering dining packages and dinner specials. The restaurants at many of the inns are destinations unto themselves, with award-wining chefs crafting exemplary farm-to-table cuisine that draw upon California’s bounty of local farms, fisherman, ranchers, and winemakers.  For just $40 per person, Murieta Inn & Spa’s 

Changes in the offering

Based on Swedish Securities Councils statement earlier today, after further discussions with interested parties, Brighter has now chosen to comply with the formal recommendation and therefore organize public trading in subscription rights in connection with the present rights issue. The significance of this is that the company will now adjust the issue offer that was published on November 18 and organize trading in subscription rights. “The important thing for Brighter is still that as much as possible of the proceeds goes to the company and thus benefits the shareholders. The change in

There are no items matching the current filter
There are no more items matching the current filter
Back to top